Gene expression meta-analysis identifies cytokine pathways and 5q aberrations involved in metastasis of ERBB2 amplified and basal breast cancer

Cancer Informatics

Volumn 12, Issue , 2013, Pages 203-219

  Thomassen, Mads ^a   Tan, Qihua ^a,b   Burton, Mark ^a   Kruse, Torben A ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Breast cancer; Gene expression; Metastasis; Microarray; Molecular subtypes; Pathway analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 12; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHROMOSOME PAIRING; CONTROLLED STUDY; ERBB2 GENE; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HAPLN1 GENE; HUMAN; HUMAN CELL; IL12 GENE; MAJOR CLINICAL STUDY; METASTASIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SURVIVAL RATE; TNFR2 GENE; UPREGULATION;

EID: 84888367959     PISSN: None     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/CIN.S12840     Document Type: Article

References (34)

1. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25): 1999-2009.
2. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005; 365(9460): 671-9.
3. Desmedt C, Piette F, Loi S, et al. TRANSBIG Consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007; 13(11): 3207-14.
4. Thomassen M, Tan Q, Eiriksdottir F, Bak M, Cold S, Kruse TA. Prediction of metastasis from low-malignant breast cancer by gene expression profiling. Int J Cancer. 2007; 120(5): 1070-5.
5. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797): 747-52.
6. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19): 10869-74.
7. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14): 8418-23.
8. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006; 7: 96.
9. Schmidt M, Böhm D, von Törne C, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008; 68(13): 5405-13.
10. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007; 8(8): R157.
11. Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer. BMC Cancer. 2008; 8: 394.
12. Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis. Breast Cancer Res Treat. 2009; 113(2): 239-49.
13. Friedrich K, Weber T, Scheithauer J, et al. Chromosomal genotype in breast cancer progression: comparison of primary and secondary manifestations. Cell Oncol. 2008; 30(1): 39-50.
14. Karlsson E, Danielsson A, Delle U, Olsson B, Karlsson P, Helou K. Chromosomal changes associated with clinical outcome in lymph node-negative breast cancer. Cancer Genet Cytogenet. 2007; 172(2): 139-46.
15. Callaghan KA, Becker TE, Ellsworth DL, Hooke JA, Ellsworth RE, Shriver CD. Genomic instability and the development of metastatic lymph node tumors. Ann Surg Oncol. 2007; 14(11): 3125-32.
16. Adélaïde J, Finetti P, Bekhouche I, et al. Integrated profiling of basal and luminal breast cancers. Cancer Res. 2007; 67(24): 11565-75.
17. Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA. Allelic loss of 16q23. 2-24. 2 is an independent marker of good prognosis in primary breast cancer. Cancer Res. 1998; 58(10): 2166-9.
18. Götte M, Yip GW. Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res. 2006; 66(21): 10233-7.
19. Cui LF, Guo XJ, Wei J, et al. Overexpression of TNF-alpha and TNFRII in invasive micropapillary carcinoma of the breast: clinicopathological correlations. Histopathology. 2008; 53(4): 381-8.
20. Parihar R, Dierksheide J, Hu Y, Carson WE. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest. 2002; 110(7): 983-92.
21. Parihar R, Nadella P, Lewis A, et al. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res. 2004; 10(15): 5027-37.
22. Ménard S, Tomasic G, Casalini P, et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res. 1997; 3(5): 817-9.
23. Aaltomaa S, Lipponen P, Eskelinen M, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer. 1992; 28A(4-5): 859-64.
24. Alexe G, Dalgin GS, Scanfeld D, et al. High expression of lymphocyte-associated genes in node-negative HER222breast cancers correlates with lower recurrence rates. Cancer Res. 2007; 67(22): 10669-76.
25. Rody A, Holtrich U, Pusztai L, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009; 11(2): R15.
26. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008; 14(16): 5158-65.
27. Bergamaschi A, Kim YH, Wang P, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer. 2006; 45(11): 1033-40.
28. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418): 61-70.
29. Loo LW, Grove DI, Williams EM, et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res. 2004; 64(23): 8541-9.
30. Cingoz S, Altungoz O, Canda T, Saydam S, Aksakoglu G, Sakizli M. DNA copy number changes detected by comparative genomic hybridization and their association with clinicopathologic parameters in breast tumors. Cancer Genet Cytogenet. 2003; 145(2): 108-14.
31. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43): 15545-50.
32. Miller LD, Smeds J, George J, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005; 102(38): 13550-5.
33. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006; 8(4): R34.
34. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006; 439(7074): 353-7.